TY - JOUR AB - During DNA repair, BRCA1 and BRCA2 interact with the tumor suppressor partner and localizer of BRCA2 (PALB2). PALB2 mutations are associated with an increased risk of breast and ovarian carcinoma, and upregulated PALB2 expression is associated with poor clinical outcomes. The present study investigated the role and prognostic value of PALB2 in pancreatic ductal adenocarcinoma (PDAC). PALB2 expression was inhibited using a small interfering RNA in PDAC cell lines, and the subsequent effects on cell proliferation and migration were investigated. Tissue microarrays from 157 patients undergoing a pancreaticoduodenectomy for PDAC were analyzed via immunohistochemistry, and PALB2 expression was compared with patient outcomes using Kaplan‑Meier curves and the multivariate Cox regression model. PALB2‑knockdown in PDAC cells had little effect on cell proliferation, but significantly decreased cell migration. Relatively high PALB2 expression was observed in PDAC tissues compared with in peritumoral tissues. Overall survival (OS) was negatively associated with PALB2 expression. TNM stage and PALB2 expression were identified as independent prognostic factors associated with OS via multivariate analysis. Overall, the present study demonstrated that PDAC cell migration was dependent on PALB2, which was further supported by the finding that elevated PALB2 expression in PDAC tissues was associated with poor survival in patients with PDAC. Therefore, PALB2 may serve as a novel prognostic marker in PDAC, which may aid with the development of therapeutic strategies for the disease. AD - Institute for Experimental Endocrinology, Charité‑Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‑Universität zu Berlin and Berlin Institute of Health, D‑13353 Berlin, Germany Department of Gastrointestinal Surgery, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361003, P.R. China Medical Department for Hematology and Oncology, Klinikum rechts der Isar, Technische University Munich, D‑81675 Munich, Germany Department of Rheumatology and Clinical Immunology, Charité‑Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‑Universität zu Berlin, and Berlin Institute of Health, D‑10117 Berlin, Germany Department of Gastroenterology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian 362000, P.R. China AU - Ge,Ouyang AU - Huang,Anle AU - Wang,Xin AU - Chen,Yuling AU - Ye,Yuanchun AU - Schomburg,Lutz DA - 2021/03/01 DO - 10.3892/ol.2021.12485 IS - 3 JO - Oncol Lett KW - prognostic marker partner and localizer of BRCA2 pancreatic ductal adenocarcinoma cell migration epithelial‑mesenchymal transition PY - 2021 SN - 1792-1074 1792-1082 SP - 224 ST - PALB2 upregulation is associated with a poor prognosis in pancreatic ductal adenocarcinoma T2 - Oncology Letters TI - PALB2 upregulation is associated with a poor prognosis in pancreatic ductal adenocarcinoma UR - https://doi.org/10.3892/ol.2021.12485 VL - 21 ER -